The value of nerve ultrasound in patients with neurofibromatosis type 1

• Conditions: neurofibromatosis type 1; Von Recklinghausen's disease; 10029299; 10029209

• Registration Number: NL-OMON48220
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

- Age >=18 years
- Diagnosed with neurofibromatosis type 1
- Treatment at the outpatient clinic of the Erasmus MC Cancer Institute (Rotterdam)

Exclusion Criteria

- comorbidity associated with (poly)neuropathy (e.g. alcoholism, diabetes mellitus)
- comorbidity mimicking neuropathic complaints (e.g. myelopathy)
- inability to give informed consent or to undergo HRUS

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameters are the number of HRUS abnormalities and their<br /><br>characteristics (cross-sectional area, presence of vascularization) and the<br /><br>presence or absence of neurological deficits.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters are:<br /><br>- the number of newly detected nerve abnormalities with HRUS after two years of<br /><br>follow-up;<br /><br>- the increase in CSA and/or vascularization of nerve abnormalities detected<br /><br>with HRUS after two years of follow-up.</p><br>